Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, with shares closing sharply higher than their offering price on the first day of trading.
The Shanghai-rooted biotech priced its initial public offering at $17.00 per share under the ticker symbol WWB. By the close of its opening session, the stock had reached $28.50, representing a gain of roughly 68 percent over the IPO price — a strong first-day performance by any market standard.
Read more Starwood Property Trust Leaders Buy Shares in Open Market →
Windward Bio operates in the immunology space, a therapeutic area that has drawn significant investor interest in recent years as drug developers pursue novel mechanisms to treat autoimmune and inflammatory diseases. The company is classified as clinical-stage, meaning it has candidates in human trials but has not yet brought a product to market.
Qiming Venture Partners, the firm's lead backer, is a prominent venture capital investor focused on technology and healthcare companies across Asia. The listing marks a cross-border milestone for the firm, bringing one of its portfolio companies to a major U.S. exchange.
The IPO adds to a string of biotech listings on U.S. markets as investor appetite for early-stage life sciences companies continues to be tested. Continue reading at All Financial Services & Investing.